Skye Bioscience, Inc.

NasdaqGM:SKYE Stock Report

Market Cap: US$26.7m

Skye Bioscience Management

Management criteria checks 1/4

Skye Bioscience's CEO is Punit Dhillon, appointed in Aug 2020, has a tenure of 5.33 years. total yearly compensation is $6.14M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $142.12K. The average tenure of the management team and the board of directors is 3 years and 1.4 years respectively.

Key information

Punit Dhillon

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage7.47%
CEO tenure5.3yrs
CEO ownership0.5%
Management average tenure3yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 01

Is Skye Bioscience (NASDAQ:SKYE) In A Good Position To Invest In Growth?

Sep 06
Is Skye Bioscience (NASDAQ:SKYE) In A Good Position To Invest In Growth?

Will Skye Bioscience (NASDAQ:SKYE) Spend Its Cash Wisely?

Apr 22
Will Skye Bioscience (NASDAQ:SKYE) Spend Its Cash Wisely?

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11
Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Punit Dhillon's remuneration changed compared to Skye Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$42m

Mar 31 2025n/an/a

-US$33m

Dec 31 2024US$6mUS$458k

-US$27m

Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$450k

-US$38m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$668kUS$433k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$9m

Dec 31 2021US$900kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$615kUS$160k

-US$7m

Sep 30 2020n/an/a

-US$207k

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$13m

Dec 31 2019US$65kn/a

US$1m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$82kn/a

-US$19m

Compensation vs Market: Punit's total compensation ($USD6.14M) is above average for companies of similar size in the US market ($USD577.67K).

Compensation vs Earnings: Punit's compensation has increased whilst the company is unprofitable.

CEO

Punit Dhillon (45 yo)

5.3yrs
Tenure
US$6,139,625
Compensation

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

Leadership Team

NamePositionTenureCompensationOwnership
Punit Dhillon
President5.3yrsUS$6.14m0.53%
$ 142.1k
Kaitlyn Arsenault
Chief Financial Officer4.2yrsUS$2.27m0.30%
$ 81.0k
Tu Diep
Chief Operating Officerless than a yearUS$2.21m0.12%
$ 32.6k
Christopher Twitty
Chief Scientific Officer3yrsno data0.25%
$ 67.8k
Brennen Brodersen
General Counselno datano datano data
Puneet Arora
Chief Medical Officer1.3yrsno datano data
3.0yrs
Average Tenure
45yo
Average Age

Experienced Management: SKYE's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Punit Dhillon
President7.9yrsUS$6.14m0.53%
$ 142.1k
Paul Grayson
Independent Chairman of the Board2.3yrsUS$2.18m0.31%
$ 81.9k
Andrew Schwab
Director2.3yrsUS$685.14k0%
$ 0
Louis Aronne
Member of Clinical & Scientific Advisory Board1.4yrsno datano data
Lee Kaplan
Member of Clinical & Scientific Advisory Board1.4yrsno datano data
Annalisa Lisa Jenkins
Independent Director1.8yrsUS$749.74k0%
$ 0
Karen Smith
Independent Director1.4yrsUS$491.33k0%
$ 0
Deborah Charych
Independent Director2.8yrsUS$690.18k0%
$ 0
Rekha Kumar
Member of Clinical & Scientific Advisory Board1.4yrsno datano data
Beverly Tchang
Member of Clinical & Scientific Advisory Board1.4yrsno datano data
Marcus Goncalves
Member of Clinical & Scientific Advisory Board1.4yrsno datano data
1.4yrs
Average Tenure
60yo
Average Age

Experienced Board: SKYE's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 13:39
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Skye Bioscience, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC